Effects of Crestor on inflammation of atherosclerotic plaques
Study identifier:D4411M00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Exploratory study of new imaging biomarkers for measurement of carotid plaque inflammation
Medical condition
Atherosclerosis
Phase
N/A
Healthy volunteers
Yes
Study drug
rosuvastatin, placebo
Sex
All
Actual Enrollment
74
Study type
Interventional
Age
18 Years - 70 Years
Date
Study Start Date: 01 Dec 2007
Primary Completion Date: -
Study Completion Date: 01 Jun 2009
Study design
Allocation: Randomized
Endpoint Classification: N/A
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: rosuvastatin 40 mg, tablet, once daily for 3 months. Other Name: Crestor |
| Placebo Comparator: 2 | Drug: placebo 40 mg, tablet, once daily for 3 months |
Contacts
Investigators
Principal Investigator
Håkan Ahlström
Uppsala University Sweden
